Chemotherapy-Induced Toxicities and Their Impact on Quality of Life in Cancer Patients: Management and Preventive Strategies

Cancer is a leading cause of death, disability, and chronic pain. A possible spelling error was discovered [1 Cardiovascular disease is the major cause of death around the globe. In wealthier countries, cancer remains the top cause of death. Cancer is more common in white men than cardiovascular disease until they reach their ninth decade of life[2]. The mortality rate of cancer patients rehabilitated in intensive care units (ICUs) is significant, but it has recently improved. Expansive care providers face a unique challenge in managing a senior cancer patient group with co-morbidities that require extensive medical and surgical treatments. The typical 30-day death rate in cancer cases in the ICU is around 50 [3].Cancer-related pain is widespread due to the pathophysiology as well as the associated interventions and treatments. According to the findings of various studies, two-thirds of patients with advanced cancer initiating therapy require a pain procedure, which is crucial for quality of life and function preservation[4].The term 'chemotherapy' refers to the work of medications to destroy or inhibit cancer cell growth. The most potent chemotherapy agents induce DNA damage or aid in chromosomal replication, resulting in programmed cell death (apoptosis). Medicines to limit cell growth pathways have recently been produced. The most effective chemotherapy medications reduce the pace of cell proliferation. This is accomplished through DNA commerce (which causes damage that cancer cells are less capable of mending than normal cells) or by interfering with cell division, which limits further cell division and frequently triggers apoptotic pathways[5].An adverse medicine response (ADR) is defined as "an appreciably dangerous or unwelcome response performing from an intervention related to the use of a medicinal product; adverse goods generally prognosticate hazard from unborn administration and leave forestallment, or specific treatment, or revision of the lozenge authority, or withdrawal of the product" [6].
The prevalence of ADRs has been relatively stable over time, with research indicating that 5 to 10 percent of people may have an ADR at admission, during hospitalization, or at discharge, despite appropriate preventative precautions. The maturity of ADRs is not reflected in major systemic occurrences, and the event frequency naturally corresponds to the standard method used to recognize similar events [7]. First, studies on quality of life may shed light on how patients respond to cancer and its treatment, as well as how these reactions relate to one another and to overall quality of life. As a result, they might have theoretical significance. Second, information on how a particular therapy affects quality of life may have an impact on judgments regarding the therapy's efficacy. For instance, if two treatment plans have the same effect on patient survival but one improves quality of life (QL) more than the other, the better QL should be chosen. In contrast, suppose. One treatment improves survival rates while the other improves quality of life; the patient and the person in charge of care can assess the costs and advantages. Third, the results of quality-of-life studies may improve supportive treatment for cancer patients. [8].
During chemotherapy, behavioral disruption was more commonly observed than emotional pain. [9] Four out of five studies found a favorable outlook on life or a fairly excellent overall quality of life. [8,9,10]

OVERVIEW OF CHEMOTHERAPY- INDUCED TOXICITIES

CHEMOTHERAPY INDUCED HAEMATOLOGICAL TOXICITY

Cytopenia is the term used to describe the hematological toxicity caused by chemotherapy. Cytopenia (Pancytopenia) is defined as a decrease in all three types of blood cells: red blood cells (anaemia), white blood cells, particularly neutrophils (leukopenia-neutropenia), and platelets (thrombocytopenia). This syndrome is one of the most significant chemotherapeutic drug consequences, and it can cause mortality and morbidity either directly or indirectly[11-14].
While killing cancer cells, chemotherapy medicines cause variable degrees of harm to normal towel cells, and bone gist cells are especially vulnerable to chemotherapeutic agents, resulting in myelosuppression, a typical toxic side effect[15].Myelosuppression not only causes leukopenia, neutropenia, thrombocytopenia, and low hemoglobin levels, but it also increases the risk of infections, fever, anemia, and susceptible weakness, impeding the successful execution of chemotherapy protocols[16].

NEUTROPENIA
Neutropenia is the most significant hematologic toxin of cancer chemotherapy, and it typically limits the number of boluses that can be administered. The severity and duration of neutropenia determine the risk of infection [17,18].Neutrophils are the first line of defense against infection, acting as the first cellular component of the seditious response and a critical component of ingrain impunity. Neutropenia suppresses the seditious response to early infections, allowing for bacterial addition and irruption. Because neutropenia lowers the signs and symptoms of infection, patients with neutropenia frequently appear with fever as the only indicator of infection[19].

ANEMIA

Chemotherapy-induced anemia (CIA) is caused by malignant irruption of normal towel, which results in blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron shortage as a result of inflammation[20]. Fatigue is the most prevalent symptom of CIA, but vertigo, loss of appetite, poor attention, and dyspnoea are all frequently reported [21].The association between anemia and fatigue is difficult to measure; fatigue has the greatest negative impact on quality of life [22].
CIA is more commonly found in hematologic, particularly myeloid, malignancies than in solid tumors[23]. Tuberculosis, lung cancer, gynaecologic, and genitourinary tumors have the highest prevalence of anemia, with at least 50 - 60 patients receiving transfusions [24].

THROMBOCYTOPENIA

Cancer patients frequently suffer from thrombocytopenia. It might be caused by the complaint itself or one of its symptoms, but the most prevalent cause is chemotherapy with bone gist (BM) suppression. This can result in deadly hemorrhage. In cases of severe thrombocytopenia, the chemotherapy cure is typically reduced to decrease the risk of bleeding or the requirement for platelet transfusion, which may diminish the remedial effect and relative cure intensity (RDI) and have a detrimental impact on the treatment process [25-26].CIT is defined as a platelet count less than 100x109/L and is graded as follows: grade 1 (75x109/L to less than 100x109/L), grade 2 (50x109/L to less than 75x109/L), grade 3 (25x109/L to less than 50x109/L), and grade 4 (less than 25x109/L) [27-28].
Cyclophosphamide (pro-drug) rules indicated an advanced toxin threat in renally bloodied instances and a reduced hazard in hepatically bloodied cases. Etoposide, melphalan, and methotrexate were linked to higher toxin levels in hepatically bloodied cases [29].

CHEMOTHERAPY INDUCED  GI  TOXICITY

Chemotherapy-induced gastrointestinal toxicity (CIGT) has a substantial physical and financial impact on cancer patients. In clinical practice, most cancer patients treated with chemotherapeutic agents experienced severe GI symptoms, including but not limited to nausea, vomiting, anorexia, GI mucositis (GIM), and diarrhoea, which significantly reduced cases' quality of life, intruded or altered the chemotherapy authority, and even resulted in death in the case of severe GI toxicity [30,31].

NAUSEA AND  VOMITING

Nausea and vomiting are two of the most prevalent and distressing side effects of chemotherapy treatment. The pathophysiology of CINV is complex, and it is mostly governed by the vomiting center (VC) in the medulla oblongata. The dorsal vagal complex (DVC), which consists of the NTS, region postrema (also known as the "chemoreceptor trigger zone"), and backward motor nexus, transfers additional and central inputs to the VC and causes vomiting. The VC integrates a number of inputs from supplemental and central pathways, leading in the emetic rebound as a response [32].

GI MUCOSITIS

GIM is a popular GI complication in individuals undergoing chemotherapy. Vault cells play an important role in maintaining the intestinal hedge and fostering intestinal rejuvenescence, which inhibits cell proliferation and induces higher seditious intercessors and apoptotic factors, thus leading to GIM. Sonis et al. previously presented a "five-stage model" for the pathophysiology of mucositis: 1) initiation, 2) upregulation and activation of messenger, 3) signal amplification, 4) ulceration with inflammation, and 5) healing [33].

CHEMOTHERAPY  INDUCED NEUROTOXICITY

The nervous system is a fundamental cell controller and the physiological function center of all systems, reaching all the microenvironments except for keratinized tissues [34]. Supplemental jitters can not only directly bind to cancer receptors by masking neurotransmitters, but they can also operate laterally on susceptible cells to control antitumor immunity, influencing cancer growth [35]. In turn, cancer and its treatment impact and reshape the neural system, resulting in pathological feedback loops that not only cause neurological malfunction but also fuel the development of malice [36]. Supplemental neuropathies are primarily produced by neurotoxic chemotherapy, known as chemotherapy-induced supplemental neuropathy (CIPN); less frequently, they manifest as paraneoplastic, vulnerable-mediated, or neoplastic neuropathies [37].

CHEMOTHERAPY  INDUCED CARDIOTOXICITY

Cardiotoxicity is a broad word that refers to "toxins that affect the heart." However, a firm definition of cardiotoxicity and the specific mechanisms involved is missing. This description relates to the chemotherapy's direct influence on the overall cardiovascular system, as well as a circular effect caused by thrombogenic state or hemodynamic inflow revision [38]. Numerous investigations have shown that the type of chemotherapeutic drug plays an important role in cardiotoxicity development. Therefore, the scholarly mechanisms involved in chemotherapy— Convinced cardiotoxicity are 1) direct cellular toxin, with accretive myocardial injury, performing in both diastolic and systolic dysfunction; 2) goods on the coagulation system, performing in ischemic events, thrombogenesis, and vascular toxin; 3) arrhythmogenic goods; 4) hypertensive goods; and 5) myocardial and/or pericardial inflammation associated with myocardial dysfunction or pericardial conclusions [39,40].

CHEMOTHERAPY  INDUCED NEPHROTOXICITY

The side effects of chemotherapy. Conventional chemotherapeutic drugs are first-line agents for treating a variety of diseases, but they produce order toxin, which occurs when order is excreted properly due to the action of hazardous chemicals [41]. Many medication-related nephrotoxicity cases lack a well-defined medium of harm or pathophysiology, making it difficult to design measures to treat or alleviate their situation. However, some factors may contribute to the increased prevalence of this adverse event, such as intravascular volume reduction, the use of non-chemotherapeutic nephrotoxic medications (anaesthetics, antibiotics, proton pump inhibitors, and bone-targeted curatives), radiographic ionic discrepancy media or radiation therapy, urinary tract inhibition, and natural renal complaint [42].

MECHANISM OF CHEMOTHERAPY INDUCED TOXICITIES

Chemotherapy-induced toxicity is caused by anticancer drugs' nonselective effect on both malignant and normal rapidly growing cells. These compounds primarily damage DNA or interfere with cell division, resulting in apoptosis. Normal tissues, including as bone marrow, gastrointestinal mucosa, and hair follicles, are also affected, resulting in complications such as myelosuppression, mucositis, and alopecia. This lack of selectivity significantly lowers the therapeutic efficacy of chemotherapy and exacerbates treatment-related issues [43].
Oxidative stress contributes significantly to chemotherapy-induced damage. Many anticancer medications generate excessive reactive oxygen species (ROS), which damage cellular components such lipids, proteins, and DNA. This imbalance between ROS formation and antioxidant defense mechanisms damages cells and contributes significantly to cardiotoxicity, nephrotoxicity, and neurotoxicity [44].Another important mechanism for toxicity is mitochondrial dysfunction. Chemotherapy drugs can impair mitochondrial respiration and ATP synthesis, causing energy depletion and the activation of apoptotic pathways in normal cells. This contributes to weariness, muscle weakness, and organ malfunction in chemotherapy patients [45].
Inflammatory reactions have a crucial role in chemotherapy-related adverse effects. Pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β promote tissue damage and systemic inflammation. This inflammatory cascade exacerbates poisoning and results in symptoms like fatigue, pain, and anorexia [46].Genetic variation among patients influences the severity of chemotherapy-induced toxicities. Variations in medication metabolism and cellular repair systems can cause therapy outcomes to differ. Pharmacogenomics helps identify high-risk patients and enables for personalized therapy, which increases safety and effectiveness [47].

IMPACT ON QUALITY OF LIFE

Chemotherapy is a vital part in improving cancer patients' health. It impairs their quality of life due to different treatment-related toxicities. Patients having chemotherapy typically encounter symptoms such as nausea, vomiting, pain, exhaustion, and psychological anguish, which have an overall impact on the patient's quality of life in terms of physical, mental, and social well-being. Patients may feel burdened as a result of the protracted treatment plan, which causes everyday function to diminish and overall health to suffer. Although chemotherapy is effective for illness treatment, it has a negative impact on the patients' well-being and life satisfaction [48].Breast cancer affects both the physical and psychological elements. In addition, it can have an impact on social functioning and mental health [49]. The number of ADRs increases, and the quality of life score decreases[50].
Chemotherapy has a major impact on patients' psychological health, including anxiety, despair, and emotional anguish. Even after therapy, patients continue to experience emotional stress, which has an impact on their long-term well-being [51].Due to adverse effects, patients may require dose reductions, treatment delays, or withdrawal of the therapy, which might have an impact on the treatment outcome directly or indirectly. Because of lower medication tolerance, patient adherence has an indirect impact on patient quality of life and survival outcomes. Managing a patient's toxicity is critical for both therapy and overall health [52].
Quality of life (QOL) is a multidimensional concept that encompasses physical, emotional, and social wellness. Treatment-related toxicities such as weariness, pain, nausea, and psychological suffering have a significant impact on cancer patients' quality of life when receiving chemotherapy. These variables impair daily activities and overall well-being, making QOL evaluation an essential component of cancer care [53].Standardised assessments, such as the EORTC QLQ-C30 and FACT-G, are widely used to assess QOL in cancer patients. These tests evaluate a range of factors, including physical function, emotional state, and symptom severity. Their use helps clinicians evaluate patient health and alter treatment strategies accordingly [54].
Fatigue is a common and distressing side effect of chemotherapy. It has an impact on physical activity, cognitive function, and emotional health, resulting in a significant reduction in quality of life. Cancer-related fatigue, unlike normal weariness, is persistent and cannot be alleviated by rest [55].
Chemotherapy patients often experience psychological distress, such as worry and depression. These qualities have a negative impact on treatment adherence and overall outcomes, stressing the importance of psychological support throughout cancer treatment [56].According to studies, an increase in adverse pharmaceutical responses is associated with lower quality of life scores. Effective treatment of these toxicities can improve patient satisfaction, adherence to therapy, and overall outcomes [57].Chemotherapy-induced toxicities can impact several organ systems. Early detection of unfavorable effects is critical to improving patient outcomes and preventing complications. The management of chemotherapy-induced toxicity relies primarily on supportive and symptomatic care. Common adverse effects include nausea and vomiting, which can be treated with antiemetics, as well as pain and exhaustion with analgesics and supportive medication. Blood transfusions and other nutritional support help to address haematological toxicities such as neutropenia and anemia. In severe cases, modifications to the treatment program are required. It includes reducing the dose, delaying treatment, or temporarily discontinuing the medicine to allow for normal tissue recovery.This decision is dependent on the severity of the toxicities, the patient's condition, and the therapeutic goal. Balancing therapeutic efficacy and patient safety is a critical step when deciding on a treatment plan or making modifications in management therapy [58]. Rapid emergency management is required when dealing with severe chemotherapy-related toxicities such as neurotoxicity or medication error to avoid irreparable damage.

Because of their lower physiological reserve, comorbidities, and susceptibility to severe toxicities, hospitalization, and medication noncompliance, aged patients necessitate personalized and geriatric-focused treatment regimens. To manage toxicities and therapeutic benefit, dose adjustments, diligent monitoring, and functional status assessments are used [59,60]. When adjusting chemotherapy regimens, the use of prophylactic medicine throughout treatment cycles helps to prevent severe toxicities, demonstrating that modern oncology stresses toxicity reduction without compromising therapeutic outcomes [61].The treatment of chemotherapy-induced toxicity focuses on supportive care and early intervention. Prompt diagnosis of undesired consequences enables adequate therapy and prevents issues. Management strategies are adapted to the patient's condition, toxicity level, and kind of malignancy [62]. Antiemetic medications are essential for treating chemotherapy-induced nausea and vomiting. The combination of 5-HT3 receptor antagonists, NK1 inhibitors, and corticosteroids has significantly improved symptom control and patient comfort [63].
Hematological toxicity, such as neutropenia and anemia, is treated with growth factors and supportive therapies. Granulocyte colony-stimulating factor (G-CSF) is commonly used to reduce the risk of infection associated with neutropenia, whereas blood transfusions and erythropoiesis-stimulating medicines are used to treat anemia [64].In extreme circumstances, dose adjustments, therapy delays, or short-term discontinuation of treatment may be required. These adjustments help to reduce toxicity while maintaining treatment efficacy. To balance benefits and risks, careful clinical judgment is required [65].
Patient education and constant monitoring are key components of toxicology management. Early symptom reporting allows for quicker management and reduces the chance of serious repercussions, resulting in better treatment outcomes [66].Regular monitoring of patient-reported symptoms is critical for preventing severe chemotherapy-related toxicities. Early detection of symptoms allows healthcare professionals to take quick action, such as changing the medicine dose or providing supportive care. This may lessen the severity of adverse effects and prevent complications that need hospitalization [67].
Preventive measures are crucial for reducing chemotherapy-related side effects. Prophylactic medications, dosage adjustments, and careful monitoring can significantly reduce adverse effects and improve treatment tolerance [68].Pharmacogenomics has emerged as an effective method for assessing toxicity risk. Genetic variations influence drug metabolism and response, allowing for more personalized treatment approaches to lessen side effects [69].
Nutritional support is critical in prevention. Patients who are malnourished are more prone to experience issues and have a poorer tolerance for treatment. Early nutritional assessment and adjustment can help patients attain better outcomes [70]. Regularly monitoring patient-reported symptoms improves in the early detection of toxicity and quick treatment. This reduces hospitalizations and improves quality of life [71].
Patient counseling and education are crucial for preventing issues. Educating patients on side effects and self-care measures leads to better adherence and treatment results [72].Maintaining good nutritional status is critical to avoiding chemotherapy-related side effects. Malnourished patients are more likely to have complications such as fatigue, weight loss, and decreased immunity. Early nutrition assessment and tailored dietary aids in immune maintenance and planning are indicated. An adequate amount of proteins and micronutrients helps each patient tolerate treatment [73,74].
The future view in chemotherapy-induced toxicity management focuses on establishing more effective and tailored treatment plans for patients in order to prevent treatment-related complications. Future research should focus on biomarker-based early detection of toxicities and the development of targeted therapies with fewer side effects [75].Cancer therapy improvements are designed to reduce toxicity while maintaining efficacy. Targeted therapies and immunotherapy have shown better safety profiles than conventional chemotherapy [76].
Biomarkers are being developed to aid in the early detection and prediction of chemotherapy-related harm. These markers help evaluate treatment responses and guide therapy decisions [77].
Artificial intelligence and machine learning are increasingly being used in oncology. They help forecast toxicity risk and optimize treatment programs based on patient data, hence improving therapeutic outcomes [78].Personalized medicine aims to tailor treatment to unique patient characteristics, reducing adverse effects and increasing efficacy. This strategy represents the future of oncology care [79].
Ongoing research seeks to enhance patient outcomes while reducing long-term harm. Improving supportive care measures will be critical in improving cancer patients' quality of life [80].

CONCLUSION

Chemotherapy-induced toxicities are prevalent and can damage several organ systems. The impact of toxicity on patients' quality of life, treatment outcomes, and overall health. Different types of toxicity have been documented, including haematological, gastrointestinal, cardiotoxic, and nephrotoxic. The severity of the toxicity and the patient's treatment plan determine how it is managed. The majority of management is symptom-based. In addition, early detection, supportive care, and treatment modification are critical for the patient's condition to avoid complications and hospitalization. Preventive methods aid in decreasing complications and increasing tolerance to therapy. Overall, enhancing toxicity control results in better patient outcomes and a higher quality of life.Beyond standard management strategies, emerging breakthroughs in cancer highlight the importance of mechanism-based and personalized methods to toxicity reduction. Understanding the molecular basis of chemotherapy-induced side effects will help develop targeted medicines that reduce damage to healthy tissues. The application of pharmacogenomics and biomarker-driven approaches has the potential to predict individual patient outcomes and improve drug selection. Furthermore, the use of digital health tools and continuous symptom monitoring can help with early detection and rapid response, minimizing the chance of significant complications. Moving forward, a personalized and precision-based oncology approach is required to find a balance between treatment efficacy and safety, thereby improving long-term patient outcomes and quality of life.

REFERENCES

1. World Health Organization. (2013). Data and statistics. Available from: http://www.who.int/research/en/
2. Driver, J. A., Djousse, L., Logroscino, G., et al. (2008). Incidence of cardiovascular disease and cancer in advanced age: Prospective cohort study. BMJ, 337, a2467. https://doi.org/10.1136/bmj.a2467
3. Staudinger, T., Stoiser, B., Müllner, M., et al. (2000). Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Critical Care Medicine, 28(5), 1322–1328. https://doi.org/10.1097/00003246-200005000-00011
4. Fischer, D. J., Villines, D., Kim, Y. O., Epstein, J. B., & Wilkie, D. J. (2009). Anxiety, depression, and pain: Differences by primary cancer. Supportive Care in Cancer, 18(7), 801–810. https://doi.org/10.1007/s00520-009-0712-5
5. Mitchison, D. (1979). Basic mechanisms of chemotherapy. Chest, 76(6 Suppl), 771–781. https://doi.org/10.1378/chest.76.6_supplement.771
6. Aronson, J. K., & Ferner, R. E. (2005). Clarification of terminology in drug safety. Drug Safety, 28(10), 851–870. https://doi.org/10.2165/00002018-200528100-00003
7. Wester, K., Jönsson, A. K., Spigset, O., Druid, H., & Hägg, S. (2007). Incidence of fatal adverse drug reactions: A population-based study. British Journal of Clinical Pharmacology, 65(4), 573–579. https://doi.org/10.1111/j.1365-2125.2007.03064.x
8. Giel, R., Frankenberg, W., Oldhoff, J., et al. (1977). The surgeon-oncologist and quality of life of patients. Nederlands Tijdschrift voor Geneeskunde, 121(34), 1315–1320.
9. Meyerowitz, B. E., Watkins, I. K., & Sparks, F. C. (1983). Quality of life for breast cancer patients receiving adjuvant chemotherapy. American Journal of Nursing, 83(2), 232–235.
10. Gilbert, H., Kagan, A., Nussbaum, H., et al. (1977). Evaluation of radiation therapy for bone metastases: Pain relief and quality of life. American Journal of Roentgenology, 129(6), 1095–1096. https://doi.org/10.2214/ajr.129.6.1095
11. Lyman, G. H., Poniewierski, M. S., & Culakova, E. (2016). Risk of chemotherapy-induced neutropenic complications. Expert Opinion on Drug Safety, 15(4), 483–492. https://doi.org/10.1517/14740338.2016.1146675
12. De Vries Schultink, A. H. M., Suleiman, A. A., Schellens, J. H. M., Beijnen, J. H., & Huitema, A. D. R. (2016). Pharmacodynamic modeling of adverse effects of anticancer drugs. European Journal of Clinical Pharmacology, 72(6), 645–653. https://doi.org/10.1007/s00228-016-2030-4
13. Vadhan-Raj, S. (2009). Management of chemotherapy-induced thrombocytopenia. Seminars in Hematology, 46(1 Suppl 2), S26–S32. https://doi.org/10.1053/j.seminhematol.2008.12.007
14. Crawford, J., Dale, D. C., & Lyman, G. H. (2004). Chemotherapy-induced neutropenia. Cancer, 100(2), 228–237. https://doi.org/10.1002/cncr.11882
15. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2020. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
16. Bocciar, R., Glaspy, J., Crawford, J., et al. (2022). Chemotherapy-induced neutropenia and febrile neutropenia. The Oncologist, 27(8), 625–636. https://doi.org/10.1093/oncolo/oyac074
17. Bodey, G. P., Buckley, M., Sathe, Y. S., & Freireich, E. J. (1966). Quantitative relationships between leukocytes and infection. Annals of Internal Medicine, 64, 328–340.
18. Blackwell, S., & Crawford, J. (1994). Filgrastim in chemotherapy setting. In: Morstyn G, Dexter TM, Foote M, editors. Clinical Practice. New York: Marcel Dekker.
19. Crawford, J., Dale, D. C., & Lyman, G. H. (2004). Chemotherapy-induced neutropenia. Cancer, 100(2), 228–237. https://doi.org/10.1002/cncr.11882
20. Gilreath, J. A., Stenehjem, D. D., & Rodgers, G. M. (2014). Diagnosis and treatment of cancer-related anemia. American Journal of Hematology, 89(2), 203–212.
21. Wright, J. R., Ung, Y. C., Julian, J. A., et al. (2007). Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with anemia. Journal of Clinical Oncology, 25(9), 1027–1032. https://doi.org/10.1200/JCO.2006.07.1514
22. Groopman, J. E., & Itri, L. M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91(19), 1616–1634.
23. Clarke, H., & Pallister, C. J. (2005). The impact of anaemia on outcome in cancer. Clinical and Laboratory Haematology, 27(1), 1–13.
24. Tas, F., Eralp, Y., Basaran, M., et al. (2002). Anemia in oncology practice. American Journal of Clinical Oncology, 25(4), 371–379.
25. Hitron, A., et al. (2011). Incidence and risk factors of chemotherapy-induced thrombocytopenia in solid tumors. Journal of Oncology Pharmacy Practice, 17(4), 312–319. https://doi.org/10.1177/1078155210380293
26. Crawford, J., et al. (2020). Relative dose intensity and survival in advanced non-small-cell lung cancer. Supportive Care in Cancer, 28(2), 925–932. https://doi.org/10.1007/s00520-019-04875-1
27. National Cancer Institute. (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of Health and Human Services.
28. Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981). Reporting results of cancer treatment. Cancer, 47(1), 207–214.
29. Nies, K., Vernooij, R., Devriese, L., et al. (2025). Chemotherapy-induced hematological toxicity in renal or hepatic impairment. Pharmaceutics, 17(10), 1280. https://doi.org/10.3390/pharmaceutics17101280
30. Ballatori, E., & Roila, F. (2003). Impact of nausea and vomiting on quality of life in cancer patients. Health and Quality of Life Outcomes, 1, 46. https://doi.org/10.1186/1477-7525-1-46
31. Cinausero, M., Aprile, G., Ermacora, P., et al. (2017). Cancer treatment-related mucosal injury. Frontiers in Pharmacology, 8, 354. https://doi.org/10.3389/fphar.2017.00354
32. Gupta, K., Walton, R., & Kataria, S. P. (2021). Chemotherapy-induced nausea and vomiting: Pathogenesis and management. Cancer Treatment and Research Communications, 26, 100278. https://doi.org/10.1016/j.ctarc.2020.100278
33. Sonis, S. T. (2004). The pathobiology of mucositis. Nature Reviews Cancer, 4(4), 277–284. https://doi.org/10.1038/nrc1318
34. Boilly, B., Faulkner, S., Jobling, P., & Hondermarck, H. (2017). Nerve dependence in cancer. Cancer Cell, 31(3), 342–354. https://doi.org/10.1016/j.ccell.2017.02.005
35. Hu, J., Chen, W., Shen, L., et al. (2022). Peripheral nervous system and breast cancer progression. Biochimica et Biophysica Acta Reviews on Cancer, 1877(6), 188828. https://doi.org/10.1016/j.bbcan.2022.188828
36. Winkler, F., Venkatesh, H. S., Amit, M., et al. (2023). Cancer neuroscience: Emerging directions. Cell, 186(8), 1689–1707. https://doi.org/10.1016/j.cell.2023.02.002
37. Sarezky, J., Sachs, G., Elinzano, H., & Stavros, K. (2021). Cancer and peripheral nerve disease. Clinics in Geriatric Medicine, 37(2), 289–300. https://doi.org/10.1016/j.cger.2021.01.003
38. Albini, A., Pannesi, G., Donatelli, F., et al. (2010). Cardiotoxicity of anticancer drugs. Journal of the National Cancer Institute, 102, 14–25. https://doi.org/10.1093/jnci/djp440
39. Gillespie, H. S., McGann, C. J., & Wilson, B. D. (2011). Diagnosis of chemotherapy-related cardiotoxicity. Current Cardiology Reviews, 7, 234–244. https://doi.org/10.2174/157340311799960672
40. Kang, Y. J. (2001). Mechanisms of cardiotoxicity. Environmental Health Perspectives, 109, 27–34. https://doi.org/10.1289/ehp.01109s127
41. Rosner, M. H., & Perazella, M. A. (2017). Acute kidney injury in patients with cancer. New England Journal of Medicine, 376(18), 1770–1781. https://doi.org/10.1056/NEJMra1613984
42. Yap, T. A., Aerts, J. G., Popat, S., & Fennell, D. A. (2017). Novel insights into mesothelioma biology and implications for therapy. Nature Reviews Cancer, 17(8), 475–488. https://doi.org/10.1038/nrc.2017.42
43. Hayes, J. D., Dinkova-Kostova, A. T., & Tew, K. D. (2019). Oxidative stress in cancer. Pharmacological Research, 145, 104526. https://doi.org/10.1016/j.phrs.2019.104526
44. Wallace, K. B. (2018). Mitochondrial mechanisms of chemotherapy toxicity. Toxicology, 409, 64–71. https://doi.org/10.1016/j.tox.2018.10.002
45. Chen, Y., Jungsuwadee, P., Vore, M., Butterfield, D. A., & St Clair, D. K. (2020). Oxidative stress in normal tissues during chemotherapy. Biomedicine & Pharmacotherapy, 121, 110987. https://doi.org/10.1016/j.biopha.2020.110987
46. Lheureux, S., Braunstein, M., & Oza, A. M. (2020). Targeting DNA repair in cancer therapy. Nature Reviews Clinical Oncology, 17(9), 515–533. https://doi.org/10.1038/s41568-020-0267-9
47. Cella, D. F., Tulsky, D. S., Gray, G., et al. (2003). Functional Assessment of Cancer Therapy scale: Development and validation. Journal of Clinical Oncology, 21(2), 279–285. https://doi.org/10.1200/JCO.2003.04.195
48. Jhaveri, K. D., & Fishbane, S. (2013). Onco-nephrology and chemotherapy-induced nephrotoxicity. Kidney International, 84, 421–422.
49. Akhlaghi, E., Lehto, R. H., Torabikhah, M., et al. (2020). Chemotherapy use and quality of life at end of life. Health and Quality of Life Outcomes, 18(1), 332. https://doi.org/10.1186/s12955-020-01580-0
50. Liew, A. C., Peh, K., Tan, B. S., Zhao, W., & Tangiisuran, B. (2019). Chemotherapy toxicity and quality of life in breast cancer patients. Supportive Care in Cancer, 27(12), 4515–4524. https://doi.org/10.1007/s00520-019-04724-1
51. Schuurhuizen, C. S., Verheul, H. M., Braamse, A. M., et al. (2018). Predictive value of cumulative toxicity for quality of life. Cancer Management and Research, 10, 3015–3021. https://doi.org/10.2147/CMAR.S166468
52. Jacquet, E., Lardy-Cléaud, A., Pistilli, B., et al. (2018). Endocrine therapy vs chemotherapy in metastatic breast cancer. European Journal of Cancer, 95, 93–101. https://doi.org/10.1016/j.ejca.2018.03.013
53. Greenspan, S. L., Brufsky, A., Lembersky, B. C., et al. (2008). Risedronate prevents bone loss in breast cancer survivors. Journal of Clinical Oncology, 26(16), 2644–2652. https://doi.org/10.1200/jco.2007.15.2967
54. Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (2004). EORTC QLQ-C30: Quality of life instrument. The Lancet Oncology, 5(6), 365–376. https://doi.org/10.1016/S1470-2045(04)01533-6
55. Curt, G. A., Breitbart, W., Cella, D., et al. (2000). Impact of fatigue on cancer patients. Cancer, 89(1), 234–244. https://doi.org/10.1002/cncr.21637
56. Linden, W., Vodermaier, A., Mackenzie, R., & Greig, D. (2012). Anxiety and depression after cancer diagnosis. Annals of Oncology, 23(4), 1027–1033. https://doi.org/10.1093/annonc/mdx702
57. Montazeri, A. (2018). Quality of life in oncology research. Supportive Care in Cancer, 26(12), 4091–4098. https://doi.org/10.1007/s00520-018-4505-0
58. Basch, E., Deal, A. M., Dueck, A. C., et al. (2018). Patient-reported outcomes in cancer care. Journal of Oncology Practice, 14(4), e234–e242. https://doi.org/10.1200/JOP.18.00562
59. Livshits, Z., Rao, R. B., & Smith, S. W. (2013). Chemotherapy-associated toxicity: Clinical approach. Emergency Medicine Clinics of North America, 32(1), 167–203. https://doi.org/10.1016/j.emc.2013.09.002
60. Livshits, Z., Rao, R. B., & Smith, S. W. (2013). Chemotherapy-associated toxicity: Clinical approach. Emergency Medicine Clinics of North America, 32(1), 167–203. https://doi.org/10.1016/j.emc.2013.09.002
61. Feliu, J., Heredia-Soto, V., Gironés, R., et al. (2019). Management of toxicity in elderly cancer patients. Clinical and Translational Oncology, 22(4), 457–467. https://doi.org/10.1007/s12094-019-02167-y
62. Yao, J., Wang, Y., Mao, T., et al. (2021). Safety management of platinum-based chemotherapy and maintenance therapy. Translational Cancer Research, 10(5), 2488–2495. https://doi.org/10.21037/tcr-20-3478
63. Hesketh, P. J., Kris, M. G., Basch, E., et al. (2017). Antiemetics: Updated clinical practice guidelines. Journal of Clinical Oncology, 35(28), 3240–3261. https://doi.org/10.1200/JCO.2017.74.4789
64. Crawford, J., Caserta, C., & Roila, F. (2018). Hematopoietic growth factors. New England Journal of Medicine, 378(12), 1135–1145. https://doi.org/10.1056/NEJMra1700355
65. Jordan, K., Jahn, F., & Aapro, M. (2019). Management of chemotherapy toxicity. Cancer Treatment Reviews, 80, 101934. https://doi.org/10.1016/j.ctrv.2019.101934
66. Klastersky, J., & Awada, A. (2020). Supportive care in cancer therapy. Supportive Care in Cancer, 28(10), 4561–4568. https://doi.org/10.1007/s00520-020-05523-8
67. Nurgali, K., Jagoe, R. T., & Abalo, R. (2018). Adverse effects of cancer chemotherapy. Critical Reviews in Oncology/Hematology, 131, 49–62. https://doi.org/10.1016/j.critrevonc.2018.05.002
68. Basch, E., Deal, A. M., Kris, M. G., et al. (2016). Symptom monitoring using patient-reported outcomes. Journal of Clinical Oncology, 34(6), 557–565. https://doi.org/10.1200/JCO.2016.70.7666
69. Relling, M. V., & Evans, W. E. (2015). Pharmacogenomics in cancer therapy. Nature Reviews Clinical Oncology, 12(6), 303–314. https://doi.org/10.1038/nrclinonc.2016.68
70. Arends, J., Bachmann, P., Baracos, V., et al. (2017). ESPEN guidelines on nutrition in cancer patients. Journal of Cachexia, Sarcopenia and Muscle, 8(6), 1069–1089. https://doi.org/10.1002/jcsm.12501
71. Denis, F., Basch, E., Septans, A. L., et al. (2019). Symptom monitoring in cancer patients. Supportive Care in Cancer, 27(4), 1047–1055. https://doi.org/10.1016/j.support.2019.02.001
72. McCorkle, R., Ercolano, E., Lazenby, M., et al. (2011). Self-management in cancer care. Journal of Clinical Oncology, 29(6), 746–754. https://doi.org/10.1200/JCO.2016.68.4023
73. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy. Nature Reviews Cancer, 18(5), 299–308. https://doi.org/10.1038/nrc.2018.20
74. Arends, J., Bachmann, P., Baracos, V., et al. (2016). ESPEN guidelines on nutrition in cancer patients. Clinical Nutrition, 36(1), 11–48. https://doi.org/10.1016/j.clnu.2016.07.015
75. Tay, L. H., Ong, A. K. W., & Lang, D. S. P. (2018). Experiences of cancer patients receiving counseling: A systematic review. JBI Database of Systematic Reviews, 16(10), 1965–2012. https://doi.org/10.11124/jbisrir-2017-003606
76. Wang, S., & Li, Y. (2022). Advances in management of chemotherapy-induced toxicities. Cancer Treatment and Research Communications, 30, 100512. https://doi.org/10.1016/j.ctarc.2022.100512
77. Schilsky, R. L. (2020). Biomarkers in cancer treatment. Drug Discovery Today, 25(6), 1082–1090. https://doi.org/10.1016/j.drudis.2020.05.010
78. Topol, E. J. (2019). High-performance medicine and artificial intelligence. npj Digital Medicine, 2, 18. https://doi.org/10.1038/s41746-019-0180-3
79. Dienstmann, R., Rodon, J., & Tabernero, J. (2020). Precision oncology approaches. Annals of Oncology, 31(5), 597–609. https://doi.org/10.1016/j.annonc.2020.02.007
80. Bluethmann, S. M., Mariotto, A. B., & Rowland, J. H. (2016). Cancer survivorship trends. Cancer, 122(7), 1043–1052. https://doi.org/10.1002/cncr.32839.